Iovance Biotherapeutics (NASDAQ: IOVA) reported Q1 EPS of ($0.36), $0.12 worse than the analyst estimate of ($0.24). Revenue for the quarter came in at $49.3 million versus the consensus estimate of $83.27 million.

For earnings history and earnings-related data on Iovance Biotherapeutics (IOVA) click here.